Aurobindo Reprimanded By SEBI Over US FDA Warning Disclosure
‘Very Limited And Restricted Information’ Revealed By Indian Firm Deemed ‘Insufficient’
Executive Summary
The Securities and Exchange Board of India has warned Aurobindo that it did not disclose sufficient information about a US FDA warning letter that it received in connection with its Unit 1 API facility in Hyderabad early this year.
You may also be interested in...
Two Of Aurobindo’s Europe Biosimilar Filings Stuck
Even as two biosimilar filings in Europe are stuck due to a lack of inspection staff and a biosimilar could be approved in the UK without a Phase III trial, Aurobindo has licensed novel drug Ryzneuta from Yifan Pharma. Meanwhile, a $650m-$700m revenue forecast for the specialty business has been pushed back as both overall revenues and profits declined during Q2.
Two Of Aurobindo’s Europe Biosimilar Filings Stuck, Licenses Ryzneuta From Yifan Pharma
Even as two biosimilar filings in Europe are stuck due to a lack of inspection staff and a biosimilar could be approved in the UK without a Phase III trial, Aurobindo has licensed novel drug Ryzneuta from Yifan Pharma. Meanwhile, a $650-700m revenue forecast for the specialty business has been pushed back as both overall revenues and profits declined during Q2.
Stada Begins Work On Romanian Hub
Stada has begun work on a facility in Romania into which the German giant is investing more than €50m to bolster the European supply chain.